- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04347031
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19
An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19
Study Overview
Status
Conditions
Detailed Description
Purpose of the study:
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.
Study aims:
- To study the efficacy of the drug Mefloquine, tablet 250 mg, for the treatment of patients with coronavirus infection (light and medium-heavy form), the appointment in the "off-label" in comparison with the drug Hydroxychloroquine tablets 200 mg, when administered in the mode "off label".
- To study the effectiveness of the drug Mefloquine, tablet 250 mg, when administered in the mode "off label", in comparison with the drug Hydroxychloroquine tablets 200 mg, when administered in the mode "off label" when applied to a schema for the treatment of patients with severe coronavirus infection.
- Evaluate the safety and tolerability of Mefloquine, 250 mg tablets, and Hydroxychloroquine, 200 mg tablets, for the treatment of patients with coronavirus infection (mild and moderate-severe forms).
- Evaluate the safety and tolerability of Mefloquine, 250 mg tablets, and Hydroxychloroquine, 200 mg tablets, for the treatment of patients with coronavirus infection (severe forms), when used as part of a regimen for the treatment of patients with severe coronavirus infection.
Study design:
An open, randomized, multicenter comparative study of the efficacy and safety of Mefloquine and Hydroxychloroquine in "off-label" mode for the treatment of patients with COVID-19 coronavirus infection
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 123098
- Burnasyan Federal Medical Biophysical Center FMBA of Russia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged 18 years and older COVID19 positive confirmed by PCR, without ARDS and sepsis.
- Hospitalization of the patient.
- Signed informed consent for participation in the study.
Exclusion Criteria:
The criteria for retiring a volunteer during the screening period are:
- Revoking informed consent of patients.
- Non-compliance of the volunteer with the inclusion criteria.
- First identified the condition and/or disease described in the criteria for inclusion.
- Positive test for HIV infection, Hepatitis B, C, syphilis.
The criteria for early termination of participation of volunteers in the study during the period of use of the study drug are:
- Withdrawal of informed consent by a volunteer.
- First identified the condition and/or disease described in the criteria for inclusion.
- Occurrence of serious adverse events.
- Adverse events that do not meet the criteria of severity, in the development of which, in the opinion of the researcher, further participation in the study may be harmful to the health or well-being of the volunteer.
- The need for patients included in the study, antibiotics of the fluoroquinolone group.
- Administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as gross violations of the Protocol that may affect the results of the study.
- the Patient receives / needs additional treatment that may affect the outcome of the study or the patient's safety
- Individual intolerance to research drugs
- Erroneous inclusion (for example, the patient was included in violation of the criteria for inclusion/non-inclusion of the Protocol).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: group 1 cohort 1
80 patients who receive Mefloquine prescribed according to the following scheme:
|
1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.
|
EXPERIMENTAL: group 1 cohort 2
80 patients who receive Hydroxychloroquine prescribed according to the following scheme: • 1st day: 800 mg of hydroxychloroquine per day, inside, in 200 mg tablets, 2 tablets 2 times a day; 2nd - 7th day: 400 mg of hydroxychloroquine per day, inside, in tablets of 200 mg, 1 tablet 2 times a day. |
|
EXPERIMENTAL: group 2 cohort 1
A concomitant therapy consisting of Mefloquine in conjunction with azithromycin and tocilizumab will be given for 80 patients.
Dosage of Mefloquine is same as for group 1 cohort 1.
|
1st day: 750 mg of mefloquine per day, inside, in tablets of 250 mg 3 times a day - 1 tablet every 8 hours.
|
EXPERIMENTAL: group 2 cohort 2
A concomitant therapy consisting of Hydroxychloroquine in conjunction with azithromycin and tocilizumab will be given for 80 patients.
Dosage of Hydroxychloroquine is same as for group 1 cohort 2.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1st primary endpoint for group 1
Time Frame: up to 10 days
|
The number of patients with development of respiratory failure requiring transfer to the ICU.
|
up to 10 days
|
2nd primary endpoint for group 1
Time Frame: up to 10 days
|
The period of clinical recovery.
|
up to 10 days
|
1st primary endpoint for group 2
Time Frame: up to 10 days
|
The period of clinical recovery.
|
up to 10 days
|
2nd primary endpoint for group 2
Time Frame: through study completion, an average of 3 months
|
Frequency of fatal outcomes associated with coronavirus infection disease (COVID19)
|
through study completion, an average of 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1st secondary endpoint for group 1
Time Frame: on days 5 and 10
|
A change in viral load by conducting PCR assay through different timeframes
|
on days 5 and 10
|
2nd secondary endpoint for group 1
Time Frame: on day 10
|
Frequency of clinical cure on day 10 from the start of therapy
|
on day 10
|
3d secondary endpoint for group 1
Time Frame: up to 10 days
|
The retention time of the reaction temperature from the start of the treatment.
|
up to 10 days
|
4th secondary endpoint for group 1
Time Frame: up to 10 days
|
Concentration of C-reactive protein in blood plasma.
|
up to 10 days
|
5th secondary endpoint for group 1
Time Frame: up to 10 days
|
Respiratory index.
|
up to 10 days
|
6th secondary endpoint for group 1
Time Frame: up to 10 days
|
Frequency appearance unwanted phenomena and serious unwanted phenomena
|
up to 10 days
|
1st secondary endpoint for group 2
Time Frame: on days 5 and 10
|
A change in viral load by conducting PCR assay through different timeframes
|
on days 5 and 10
|
2nd secondary endpoint for group 2
Time Frame: up to 10 days
|
Respiratory index.
|
up to 10 days
|
3d secondary endpoint for group 2
Time Frame: up to 10 days
|
The retention time of the reaction temperature from the start of treatment.
|
up to 10 days
|
4th secondary endpoint for group 2
Time Frame: up to 10 days
|
Concentration of C-reactive protein in blood plasma.
|
up to 10 days
|
5th secondary endpoint for group 2
Time Frame: up to 10 days
|
Number of patients required transition to alternative therapy schedule
|
up to 10 days
|
6th secondary endpoint for group 2
Time Frame: up to 10 days
|
Frequency of adverse events and serious adverse events
|
up to 10 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Tatiana Astrelina, MD PhD,DSc., Burnasyan FMBC SRC FMBA of Russia
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia
- Lung Diseases
- Respiratory Insufficiency
- Pneumonia, Viral
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Azithromycin
- Hydroxychloroquine
- Mefloquine
Other Study ID Numbers
- FL-01/20
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia, Viral
-
Hospices Civils de LyonTerminatedCOVID-19 | Viral Pneumonia Human CoronavirusFrance
-
University of Texas Southwestern Medical CenterWithdrawnBacterial Pneumonia | Viral PneumoniaUnited States
-
Cairo UniversityUnknown
-
Zhong WangNot yet recruiting
-
Wecare Probiotics Co., Ltd.Not yet recruitingViral Pneumonia
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedCoronavirus Infections | COVID-19 | Viral Pneumonia Human CoronavirusMexico
-
Francesco De CobelliCompleted
-
South Egypt Cancer InstituteRecruiting
-
University Hospital, LilleCompleted
-
University of TriesteCentro di Riferimento Oncologico - Aviano; National Institute for the Infectious...CompletedSevere Acute Respiratory Syndrome | Covid19 | Viral Pneumonia Human CoronavirusItaly
Clinical Trials on Mefloquine
-
Institute of Tropical Medicine, BelgiumCompletedHIV InfectionsZambia
-
Treague LtdMedicines for Malaria VentureCompletedHealthy SubjectsUnited Kingdom
-
London School of Hygiene and Tropical MedicineNoguchi Memorial Institute for Medical ResearchCompleted
-
BiogenElan PharmaceuticalsTerminatedProgressive Multifocal LeukoencephalopathyUnited States, Brazil, Italy, Spain, Germany
-
University of OxfordInstitut Pasteur; FHI 360; Mahidol University; World Health Organization; NCHADS... and other collaboratorsCompletedFalciparum MalariaCambodia
-
Hospital Clinic of BarcelonaCenters for Disease Control and Prevention; Ifakara Health Institute; Kenya Medical... and other collaboratorsCompletedHIV Infections | Pregnancy | MalariaBenin, Gabon, Kenya, Mozambique, Tanzania
-
Centers for Disease Control and PreventionWithdrawn
-
U.S. Army Medical Research and Development CommandSmithKline BeechamCompleted
-
Mepha Ltd.Centre Mère et Enfant de la Fondation Chantal BiyaCompleted
-
University of OxfordMahidol University; Medicines for Malaria VentureWithdrawnUncomplicated Falciparum MalariaCambodia